EVALUATE Act

Bill: 116-hr-7971
Sponsor: full_name: Rep. Krishnamoorthi, Raja [D-IL-8]
Introduced: 2020-08-07
Policy area: Health
Subjects: Advisory bodies

Cardiovascular and respiratory health

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Emergency medical services and trauma care

Food and Drug Administration (FDA)

Government information and archives

Immunology and vaccination

Infectious and parasitic diseases

Licensing and registrations

Medical research

Public participation and lobbying
Latest action: action_date: 2020-08-07
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2020-08-07
action_desc: Introduced in House
text: <p><b>Expeditious Vaccine Advice with Legitimate, Unbiased, Apolitical, and Technical Expertise Act or the EVALUATE Act</b> </p> <p>This bill requires the Food and Drug Administration, before licensing or authorizing any COVID-19 (i.e., coronavirus disease 2019) vaccine, to receive advisory committee recommendations concerning the vaccine's safety and effectiveness.</p>

tv_txt: I 116th CONGRESS 2d Session H. R. 7971 IN THE HOUSE OF REPRESENTATIVES August 7, 2020 Mr. Krishnamoorthi (for himself, Mr. Connolly , Ms. Tlaib , Ms. Pressley , Ms. Porter , Mr. Khanna , and Mr. DeSaulnier ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To direct the Food and Drug Administration to solicit and consider the recommendations of the Vaccines and Related Biological Products Advisory Committee before taking certain actions with respect to COVID–19 vaccines, and for other purposes.

1. Short title This Act may be cited as the Expeditious Vaccine Advice with Legitimate, Unbiased, Apolitical, and Technical Expertise Act or the EVALUATE Act . 2. Required consideration of advisory committee recommendations (a) Vaccine licensure or authorization Before licensing or authorizing any vaccine for COVID–19 or SARS–CoV–2 infection (in this section referred to as a COVID–19 vaccine ), the Commissioner of Food and Drugs shall— (1) solicit recommendations from the Vaccines and Related Biological Products Advisory Committee on whether the available data are adequate to support the safety and effectiveness of the COVID–19 vaccine and whether additional studies to further evaluate safety and effectiveness should be required before or after licensing or authorization; (2) receive such recommendations at an open meeting; (3) give public notice of such meeting at least 3 business days in advance of the meeting; and (4) publicly document how such recommendations were considered when licensing or authorizing the COVID–19 vaccine. (b) Minor or technical changes Subsection (a) does not apply— (1) to minor or technical changes to a license or authorization that is in effect; or (2) in cases involving a change to a license or authorization if the Commissioner of Food and Drugs publishes a determination that the change is not substantial and a meeting under subsection (a) would not be appropriate. (c) Provision of information (1) In general In connection with a meeting of the Vaccines and Related Biological Products Advisory Committee convened for purposes of subsection (a), the Commissioner of Food and Drugs shall— (A) provide to the Advisory Committee, at least 3 business days prior to the meeting, any data, summaries of data, briefing documents, and other information to be presented at the meeting by the Commissioner and the sponsor of the COVID–19 vaccine, and make reasonable efforts to provide any additional data, summaries of data, or information requested by the Advisory Committee before the meeting; and (B) promptly make available on the Food and Drug Administration’s website minutes, audiovisual recordings, transcripts, data, summaries of data, briefing documents, and other information or documents made available to or prepared for or by the Advisory Committee. (2) Exception The Commissioner need not make available minutes, audiovisual recordings, transcripts, data, summaries of data, briefing documents, and other information or documents pursuant to paragraph (1)(B) if the Commissioner— (A) determines that the minutes, audiovisual recordings, transcripts, data, summaries of data, briefing documents, or other information or documents should be withheld from disclosure in accordance with section 552b(c) of title 5, United States Code; and (B) promptly makes available on the public website of the Food and Drug Administration a written explanation of the reasons for not disclosing the minutes, audiovisual recordings, transcripts, data, summaries of data, briefing documents, or other information or documents.